Second-line chemotherapy with a hybrid-alternating regimen of bolus 5FU modulated by methotrexate and infusional 5FU modulated by folinic acid in patients with metastatic colorectal cancer pretreated with 5FU: A phase 2 study

Oncology

Volumn 63, Issue 3, 2002, Pages 219-225

  Carlomagno, C ^a   Lauria, R ^a   De Laurentiis, M ^a   Arpino, G ^a   Massarelli, E ^a   Ferrara, C ^a   Milano, A ^a   Vernaglia Lombardi, A ^a   Costanzo, R ^a   Catalano, G ^b   Bianco, A R ^a   De Placido, Sabino ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

5 Fluorouracil; Folinic acid; Metastatic colorectal cancer; Methotrexate; Phase 2 study; Second line chemotherapy

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINATE CALCIUM; FOLINIC ACID; IRINOTECAN; METHOTREXATE;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DRUG INFUSION; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; HYPERTRANSAMINASEMIA; LEUKOPENIA; METABOLIC DISORDER; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DIARRHEA; DISEASE PROGRESSION; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; LEUCOVORIN; METHOTREXATE; MIDDLE AGED; NAUSEA; NEOPLASM STAGING; SURVIVAL RATE; TREATMENT OUTCOME; VOMITING;

EID: 0036970909     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000065468     Document Type: Article

References (27)

1. The advanced Colorectal Cancer Meta-Analysis project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 1992;10:896-903.
2. The advanced Colorectal Cancer Meta-Analysis Project: Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 1994;12:960-969.
3. The Meta-Analysis Group in Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16:301-308.
4. De Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, Morvan F, Louvet C, Guillot T, Francois E, Bedenne L: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study. J Clin Oncol 1997;15:808-815.
5. Douillard JY, Cunnigham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichaeal J, Alaki M, Gruia G, Awad L, Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomized trial. Lancet 2000; 355:1041-1047.
6. Saltz LB, Cox JV, Blanke DO, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000;343:905-914.
7. DeGramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Luovet C, Hendler D, de Braud F, Wilson C; Morvan F, Bonetti A: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;8:2938-2947.
8. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Levi F: Phase III multicenter randomized trial of oxaliplatin added to chrono-modulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;8:136-147.
9. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, Award L, Herait P, Jacques C: Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 2000;352:1407-1412.
10. Cunnigham D, Pyrhonen S, James RD, Punt CJA, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Thopam CA, Awad L, Jacques C, Herait P: Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 2000; 3562:1413-1418.
11. Aschele C, Sobrero A, Feran M, Bertino JR: Novel mechanism(s) of resistance to fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose-schedules. Cancer Res 1992;52: 1855-1864.
12. Moran RG, Scanlon KL: Schedule-dependant enhancement of the cytotoxicity of fluoropyrimidines to human carcinoma cells in the presence of folinic acid. Cancer Res 1991;51:4618-4623.
13. Sobrero A, Aschele A, Guglielmi A, Mori AM, Melioli CG, Rosso R, Bertino JR: Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells. JNCI 1994; 23:1937-1944.
14. Sobrero A, Aschele C, Guglielmi A, Mori AM, Tixi LM, Bolli EA, Rosso R, Mammoliti S, Rollandi GA, Bertoglio S, Bruzzi P, Bertino JR: Schedule-selective biochemical modulation of 5-fluorouracil: A phase II study in colorectal cancer. Clin Cancer Res 1995;1:955-960.
15. Sobrero A, Zaniboni A, Frassinetti GL, Aschele C, Guglielmi A, Giuliani R, Ravaioli A, Lanfranco C, Caroti C, Arnoldi E, Barni S, Gallo L, Pessi MA, Turci D, Cortesi E, Grossi F, Frontini L, Piazza E, Bruzzi P, La Bianca R: Schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer: A randomized study. Ann Oncol 2000;11:1413-1420.
16. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 1981;47:207-214.
17. Simon R: Optimal two-stage designs for phase II clinical trials. Controll Clin Trials 1989;10: 1-10.
18. Kaplan EL, Meier P: Non parametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-481.
19. De Gramont A, Vignoud J, Tournigard C, Louvet C, André C, Varette C, Raymond E, Moreau S, Le Bail N, Krulik M: Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997; 33(2):214-219.
20. Maindrault-Goebel F, Louvet C, André T, Carola E, Lotz JP, Molitor JL, Garcia ML, Gilles-Amar V, Izrael V, Krulik M, De Gramont A: Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). Eur J Cancer 1999;35(9): 1338-1342.
21. André T, Louvet C, Raymond E, Tournigand C, De Gramont A: Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil. Ann Oncol 1998;9:1251-1253.
22. Mosconi S, Cascinu S, Zaniboni A, Catalano V, Giordani P, Beretta GD, Martignoni G, Pancera G, Baldelli AM, Poletti P, Curti C, Labianca R: The value of oxaliplatin in combination with continuous infusion ± bolus 5-fluorouracil and levo-folinic acid in metastatic colorectal cancer progressing after 5-FU-based chemotherapy: A GISCAD (Italian Group for the Study of Digestive Tract) cancer phase II trial. Tumori 2000;86:465-469.
23. Brienza S, Bensmaine MA, Soulié P, Louvet C, Gamelin E, Francois E, Ducreux M, Marty M, André T, De Braud F, Bleiberg H, Segal V, Itzhaki M, Cvitkovic E: Oxaliplatin added to 5-fluorouracil-based therapy in the treatment of 5-fluorouracil-pretreated patients with advanced colorectal carcinoma: Results from the European compassionate-use program. Ann Oncol 1999;10:1311-1316.
24. Conti JA, Kemeny NE, Saltz LB, André A, Grossano DD, Bertino JR: Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer. Cancer 1995;75: 769-774.
25. Seitz JF, Perrier H, Giovannini M, Capodanno G, Bardou VJ: 5-Fluorouracil, high-dose folinic acid and mitomycin-C combination in previously treated patients with advanced colorectal carcinoma. J Chemother 1998;10:258-265.
26. Thirion P, Cunnigham D, Findlay M, Norman A, Falcone A, Logue JP, Tralongo P, Aschele C, Piedbois P: Pooled analysis of phase II trials with low-dose 5-fluorouracil continuous infusion as a second line chemotherapy in advanced colorectal cancer. Proc ASCO 1999;19:#912.
27. Machover D, Diaz-Rubio E, De Gramont A, Schilf A, Gastiaburu JJ, Brienza S, Itzhaki M, Metzger G, N'Daw D, Vignoud J, Abad A, Francois E, Gamelin E, Marty M, Sastre J, Seitz JF, Ychou M: Two consecutive phase II studies of oxaliplatin for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996;7:95-98.